Strengthening Families & Communities LLC Has $93,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Strengthening Families & Communities LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 96.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 178 shares of the medical research company’s stock after selling 4,702 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Thermo Fisher Scientific were worth $93,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. AMF Tjanstepension AB bought a new position in Thermo Fisher Scientific during the 3rd quarter worth about $42,409,000. Exchange Traded Concepts LLC boosted its position in shares of Thermo Fisher Scientific by 8.0% during the third quarter. Exchange Traded Concepts LLC now owns 2,137 shares of the medical research company’s stock worth $1,322,000 after buying an additional 159 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its position in Thermo Fisher Scientific by 1.9% in the 3rd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 51,595 shares of the medical research company’s stock valued at $31,915,000 after buying an additional 969 shares during the last quarter. Redhawk Wealth Advisors Inc. acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $218,000. Finally, Woodstock Corp grew its stake in shares of Thermo Fisher Scientific by 2.1% during the 3rd quarter. Woodstock Corp now owns 15,691 shares of the medical research company’s stock worth $9,706,000 after acquiring an additional 328 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on TMO. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Citigroup raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a report on Friday, January 31st. Bernstein Bank increased their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Raymond James reaffirmed an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $658.00.

Thermo Fisher Scientific Stock Down 3.2 %

TMO stock opened at $553.02 on Tuesday. The business’s fifty day moving average price is $547.34 and its two-hundred day moving average price is $572.24. The stock has a market capitalization of $211.53 billion, a price-to-earnings ratio of 33.46, a PEG ratio of 3.18 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock worth $11,231,699 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.